Search





Search





Markets
/
Stocks
/
nasdaq-slno
/

Soleno Therapeutics Inc

SLNO

Add to Watchlist

52.780USD

+0.210+0.40%

Close 04/17, 16:00（ET）Quotes delayed by 15 min

2.76BMarket Cap

131.00P/E TTM



Soleno Therapeutics Inc

52.780

+0.210+0.40%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Soleno Therapeutics Inc

Currency: USD Updated: 2026-04-17

Key Insights

Soleno Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 19 out of 390 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 62.10.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Soleno Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

19 / 390

Overall Ranking

87 / 4524

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Soleno Therapeutics Inc Highlights

StrengthsRisks

Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 131.00, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 66.89M shares, decreasing 9.70% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 131.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.73.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

62.100

Target Price

+18.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-04-17

The current financial score of Soleno Therapeutics Inc is 9.17, ranking 13 out of 390 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

9.17

Change



Financials

9.13

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Soleno Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-04-17

The current valuation score of Soleno Therapeutics Inc is 6.81, ranking 213 out of 390 in the Biotechnology & Medical Research industry. Its current P/E ratio is 131.00, which is 0.00% below the recent high of 131.00 and 123.03% above the recent low of -30.17.

Score

Industry at a Glance

Previous score

6.81

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 19/390

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-04-17

The current earnings forecast score of Soleno Therapeutics Inc is 6.36, ranking 334 out of 390 in the Biotechnology & Medical Research industry. The average price target is 110.00, with a high of 145.00 and a low of 75.00.

Score

Industry at a Glance

Previous score

6.36

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

62.100

Target Price

+18.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

550

Total

Median

Average

Company name

Ratings

Analysts

Soleno Therapeutics Inc

SLNO

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-04-17

The current price momentum score of Soleno Therapeutics Inc is 9.89, ranking 1 out of 390 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 60.58 and the support level at 37.21, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.87

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

2.311

Buy

RSI(14)

77.934

Buy

STOCH(KDJ)(9,3,3)

92.599

Overbought

ATR(14)

2.045

High Vlolatility

CCI(14)

48.362

Neutral

Williams %R

0.087

Overbought

TRIX(12,20)

1.938

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

52.636

Buy

MA10

52.552

Buy

MA20

42.797

Buy

MA50

40.075

Buy

MA100

43.190

Buy

MA200

55.825

Sell

Institutional Confidence

Currency: USD Updated: 2026-04-17

The current institutional shareholding score of Soleno Therapeutics Inc is 10.00, ranking 1 out of 390 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 129.57%, representing a quarter-over-quarter increase of 3.47%. The largest institutional shareholder is PRFDX, holding a total of 3.26M shares, representing 6.30% of shares outstanding, with 34.14% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

7.18M

+18.53%

Fidelity Management & Research Company LLC

6.50M

-0.43%

Wellington Management Company, LLP

3.32M

+43.71%

T. Rowe Price Associates, Inc.

Star Investors

3.26M

-15.28%

BlackRock Institutional Trust Company, N.A.

3.26M

+10.75%

The Vanguard Group, Inc.

Star Investors

3.05M

+8.98%

Avoro Capital Advisors LLC

2.90M

+12.50%

State Street Investment Management (US)

2.65M

+21.93%

Fidelity Institutional Asset Management

1.47M

+7.88%

Nantahala Capital Management, LLC

1.31M

+52.13%

Risk Assessment

Currency: USD Updated: 2026-04-17

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Soleno Therapeutics Inc is 4.54, ranking 80 out of 390 in the Biotechnology & Medical Research industry. The company's beta value is -2.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.